• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SVP, General Counsel Lee Chan Henry was granted 46,878 units of Ordinary Shares, increasing direct ownership by 20% to 283,920 units (SEC Form 4)

    6/12/25 5:49:30 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lee Chan Henry

    (Last) (First) (Middle)
    C/O BEONE MEDICINES I GMBH
    AESCHENGRABEN 27, 21ST FLOOR

    (Street)
    BASEL V8 4051

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BeOne Medicines Ltd. [ ONC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 06/10/2025 A 46,878 A $0 283,920 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Share Option (Right to Buy) $20.26(2) 06/10/2025 A 88,244(2) (3) 06/09/2035 Ordinary Shares 88,244 $0 88,244 D
    Explanation of Responses:
    1. Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
    2. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.
    3. These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
    Remarks:
    /s/ Qing Nian, as Attorney-in-Fact 06/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on BeiGene with a new price target

      RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

      4/7/25 8:43:36 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene upgraded by BofA Securities with a new price target

      BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously

      3/3/25 7:35:01 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    SEC Filings

    See more
    • SEC Form 144 filed by BeOne Medicines Ltd.

      144 - BeOne Medicines Ltd. (0001651308) (Subject)

      7/9/25 4:15:42 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BeOne Medicines Ltd.

      144 - BeOne Medicines Ltd. (0001651308) (Subject)

      7/8/25 4:21:51 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BeOne Medicines Ltd.

      144 - BeOne Medicines Ltd. (0001651308) (Subject)

      6/23/25 4:08:23 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

      New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival Second approval for TEVIMBRA in the European Union this year BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper part of the throat

      7/10/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

      BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising new data from pipeline assets in breast, lung, and GI cancer franchises, including CDK4 inhibitor, B7-H4 ADC, and novel PRMT5 inhibitor, will be featured Pipeline is at an exciting inflection point with 20 near-term milestones in the next 18 months In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&D Day. The event comes at a pivotal moment for the Com

      6/26/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

      BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. The CHMP positive opinion will now be reviewed by the European Commission, which will grant the marketing authorization for the tablet formulation in the European Union and in the European Economic Area countries Norway and Iceland. "The CHMP's positive opinion of our new tablet formulation of BRUKINSA is an important step toward bringing this thou

      6/25/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Oyler John sold $7,044,591 worth of American Depositary Shares (27,802 units at $253.38), closing all direct ownership in the company (SEC Form 4)

      4 - BeOne Medicines Ltd. (0001651308) (Issuer)

      7/11/25 5:14:15 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Head of R&D Wang Lai sold $267,280 worth of American Depositary Shares (1,028 units at $260.00), closing all direct ownership in the company (SEC Form 4)

      4 - BeOne Medicines Ltd. (0001651308) (Issuer)

      6/25/25 5:09:53 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and COO Wu Xiaobin sold $354,380 worth of American Depositary Shares (1,363 units at $260.00), closing all direct ownership in the company (SEC Form 4)

      4 - BeOne Medicines Ltd. (0001651308) (Issuer)

      6/25/25 5:08:54 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Financials

    Live finance-specific insights

    See more
    • BeiGene Announces First Quarter 2025 Financial Results and Business Updates

      First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

      5/7/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Announce First Quarter 2025 Financial Results on May 7

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

      4/17/25 6:01:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673 Advanced six and 13 New Molecular Entities (NMEs) into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025 Full year 2025 revenue guidance of $4.9 billi

      2/27/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care